WallStreetZenWallStreetZen

NASDAQ: XTLB
Xtl Biopharmaceuticals Ltd Earnings & Revenue

XTLB earnings and revenue history

Current Revenue
$0.0
Current Earnings
-$1.3M
Current Profit Margin
0%

XTLB Return on Equity

Current Company
-28.9%
Current Industry
-33%
Current Market
188%
XTLB's Return on Equity (-28.9%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when XTLB announces earnings.

XTLB Return on Assets

Current Company
-25%
Current Industry
0.2%
XTLB is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

XTLB Return on Capital Employed

Current Company
0%
Current Industry
12.2%

XTLB vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
XTLB$0.00-$1.35M-$1.35MN/AN/A
IMRN$2.34MN/A-$2.54M+12.68%N/A
EDSA$0.00-$7.52M-$7.72M-100.00%N/A
NNVC$0.00-$8.55M-$9.36MN/AN/A
TNXP$7.77M-$112.37M-$116.66MN/AN/A

Xtl Biopharmaceuticals Earnings & Revenue FAQ

What was XTLB's earnings growth in the past year?

As of Q2 2024, Xtl Biopharmaceuticals's earnings has grown year over year. Xtl Biopharmaceuticals's earnings in the past year totalled -$1.35 million.

If you're new to stock investing, here's how to buy Xtl Biopharmaceuticals stock.

What was XTLB's revenue growth in the past year?

As of Q2 2024, Xtl Biopharmaceuticals's revenue has grown null year over year. Xtl Biopharmaceuticals's revenue in the past year totalled $0.00.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.